Who are Leuko Labs's investors?

Leuko Labs's investors include Good Growth Capital, Dorm Room, MassVentures.

How much funding has Leuko Labs raised?

Leuko Labs has disclosed $1.2M raised across 1 round.

Where is Leuko Labs headquartered?

Leuko Labs is headquartered in Boston, US.

Leuko Labs

Boston, US · Founded 2017 · Delaware corporation · 3 known investors

Find your way into Leuko Labs

1,159 people in our graph share verified history with the Leuko Labs team — schools, employers, funds. One of them is your warm intro.

Rolanda Fuunlockedknows Ian Butterworth · together at Massachusetts Institute of Technology (overlapped)

knows the team · via Massachusetts Institute of Technology (MIT)

×4knows the team · via Massachusetts General Hospital

×4knows the team · via Universidad Complutense de Madrid

×2knows the team · via Universidad Autonoma de Madrid

Leuko develops a noninvasive white blood cell monitor to track neutropenia risk in cancer patients and others undergoing treatment. The MIT spinout builds medical device hardware and AI imaging software for oncology and hematology care.

AI & Machine Learning Biotech Digital Health Medical Devices

Founders & leadership

Leuko Labs was founded in 2017 by Carlos Castro Gonzalez, Ian Butterworth, Aurelien Bourquard, and Alvaro Sanchez-Ferro.

Carlos Castro Gonzalez inCo-Founder and CEOCarlos Castro Gonzalez holds a PhD in Biomedical Engineering from Technical University of Madrid and completed postdoctoral work at MIT leading multidisciplinary teams on medical imaging technologies. He co-founded and serves as CEO of Leuko Labs, an MIT spinout developing a noninvasive white blood cell monitor for cancer patients, and previously worked on AI algorithms for cardiac imaging and ultrasound diagnostics.

Ian Butterworth inCofounder & CTOChief Technology Officer at Leuko Labs, an MIT spinout developing medical device hardware and AI imaging software for monitoring white blood cell counts in cancer patients and others undergoing treatment.

Aurelien Bourquard inChief Data ScientistAurelien Bourquard is Chief Data Scientist at Leuko Labs, an MIT spinout developing noninvasive white blood cell monitoring technology for oncology care. He has expertise in biomedical engineering, signal processing, image processing, and computational optics, with programming experience in MATLAB, Java, and C/C++.

Alvaro Sanchez-Ferro inChief Medical OfficerAlvaro Sanchez-Ferro is a physician and neurologist trained in Madrid who completed a competitive research fellowship at MIT. He has co-developed medical devices and software, including diagnostic tools for Parkinson's disease and a noninvasive optical monitor for white blood cell counts.

Paul Hartung inNamed on SEC filing

Board

Amy Salzhauer inBoard directorManaging Partner at Good Growth Capital

Investors · 3

Good Growth Capital✓ verifiedCharlestonvia Amy Salzhauer · board

Dorm RoomBrooklyn · $90K – $250K

MassVenturesWaltham · $250K – $500K

Reported raises · per SEC filings

Form D private placements

$1.2M disclosed across 1 round · 2019

▶$1.2MraisedFeb 2019 · 14 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Carlos Castro GonzalezExecutive Officer, Director
Ian ButterworthExecutive Officer, Director
Amy SalzhauerDirector
Paul HartungDirector

Offering amount: $1.7M
Amount sold: $1.2M
First sale: Feb 2019
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

4 people who came through Leuko Labs went on to found or lead other companies.

Amy SalzhauerDirectorFounded Good Growth Capital Carlos Castro GonzalezChief Executive OfficerFounded Leuko Aurelien BourquardChief Data ScientistFounded Leuko Alvaro Sanchez-FerroChief Medical OfficerFounded Leuko

Competitors · 1

by search overlap

Labcorp5 shared keywordsLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.

Companies competing with Leuko Labs for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase II	2020	$2M
National Institutes of Health (NIH)National Institutes of Health	Phase I	2018	$213.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Leuko Labs do?: Leuko develops a noninvasive white blood cell monitor to track neutropenia risk in cancer patients and others undergoing treatment. The MIT spinout builds medical device hardware and AI imaging software for oncology and hematology care.
Who founded Leuko Labs?: Leuko Labs was founded by Carlos Castro Gonzalez, Ian Butterworth, Aurelien Bourquard, Alvaro Sanchez-Ferro in 2017.
Who are Leuko Labs's investors?: Leuko Labs's investors include Good Growth Capital, Dorm Room, MassVentures.
How much funding has Leuko Labs raised?: Leuko Labs has disclosed $1.2M raised across 1 round.
Where is Leuko Labs headquartered?: Leuko Labs is headquartered in Boston, US.